DNDN – Dendreon Corporation is a biotechnology company focused on therapeutics that may improve cancer treatment options for patients.
The company’s Flagship drug -PROVENGE- approved by the FDA for the treat of prostate cancer. This is a very expensive treatment, obviously very lucrative for the company. There are some issues concerning the payment from the Medicare for this expensive treatment that is what brought the Stock to 52WK LOWS.
We believe even if the payments from the Medicare are reduced, still the payments would be significant, also, the company has other drugs under development for the treatment of ovarian, breast and bladder cancers/tumors. We think at this level the stock is under valued and could bounce back fast, must be on your watch list.
You are missing the Premium Alerts!Sign-up, Get Alerts that MakeMoney!®
we get compensated by the companies we feature.Always Read the full Disclosure/Disclaimer. Thanks
